Benzinga
Published Jan 22, 2024 16:01
Updated Jan 22, 2024 17:10
Competitor Analysis: Evaluating Pfizer And Competitors In Pharmaceuticals Industry
Benzinga - by Benzinga Insights, Benzinga Staff Writer.
In the dynamic and fiercely competitive business environment, conducting a thorough analysis of companies is crucial for investors and industry enthusiasts. In this article, we will perform an extensive industry comparison, evaluating Pfizer (NYSE:PFE) in relation to its major competitors in the Pharmaceuticals industry. By closely examining crucial financial metrics, market position, and growth prospects, we aim to offer valuable insights for investors and shed light on company's performance within the industry.
Pfizer Background Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Pfizer Inc | 15.45 | 1.65 | 2.36 | -2.43% | $-1.1 | $3.96 | -41.55% |
Eli Lilly and Co | 113.87 | 53.18 | 17.71 | -0.52% | $0.96 | $7.64 | 36.84% |
Novo Nordisk A/S | 43.85 | 35.14 | 15.41 | 24.5% | $32.76 | $49.02 | 28.89% |
Johnson & Johnson | 30.33 | 5.46 | 4.29 | 35.56% | $7.24 | $14.74 | 6.78% |
Merck & Co Inc | 66.05 | 7.30 | 5.11 | 11.87% | $6.95 | $11.7 | 6.71% |
Novartis AG | 28.04 | 5.83 | 4.22 | 3.91% | $4.88 | $8.97 | 12.14% |
AstraZeneca PLC | 35.21 | 5.55 | 4.61 | 3.68% | $3.33 | $9.4 | 4.64% |
Bristol-Myers Squibb Co | 12.72 | 3.52 | 2.34 | 6.32% | $4.85 | $8.46 | -2.25% |
Zoetis Inc | 38.37 | 17.03 | 10.44 | 12.28% | $0.9 | $1.51 | 7.44% |
GSK PLC | 10.54 | 4.89 | 2.16 | 11.34% | $2.55 | $5.88 | 4.06% |
Takeda Pharmaceutical Co Ltd | 35.92 | 0.97 | 1.65 | -0.69% | $202.28 | $699.51 | 4.07% |
Viatris Inc | 7.55 | 0.66 | 0.89 | 1.59% | $1.22 | $1.69 | -3.34% |
Dr Reddy's Laboratories Ltd | 18.48 | 3.71 | 3.52 | 5.94% | $23.28 | $40.37 | 9.11% |
Jazz Pharmaceuticals PLC | 140.39 | 2.10 | 2.14 | 4.19% | $0.33 | $0.87 | 3.35% |
Amphastar Pharmaceuticals Inc | 21.50 | 4.43 | 4.82 | 8.31% | $0.09 | $0.11 | 50.3% |
Corcept Therapeutics Inc | 30.52 | 5.45 | 6.14 | 7.06% | $0.03 | $0.12 | 21.5% |
Average | 42.22 | 10.35 | 5.7 | 9.02% | $19.44 | $57.33 | 12.68% |
th, td { padding: 8px; text-align: left; }
th { background-color: #293a5a; color: #fff; text-align: left; }
tr:nth-child(even) { background-color: #f2f4f8; }
tr:hover { background-color: #e1e4ea; }
td:nth-child(3), td:nth-child(5) { text-align: left; }
.dividend-amount { font-weight: bold; color: #0d6efd; }
.dividend-frequency { font-size: 12px; color: #6c757d; } Through an analysis of Pfizer, we can infer the following trends:
The debt-to-equity (D/E) ratio gauges the extent to which a company has financed its operations through debt relative to equity.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
In terms of the Debt-to-Equity ratio, Pfizer can be assessed by comparing it to its top 4 peers, resulting in the following observations:
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read the original article on Benzinga
Written By: Benzinga
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.